Rheumatoid vasculitis: An update

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Purpose of review Rheumatoid vasculitis is the most serious extra-articular complication of rheumatoid arthritis, with high morbidity and mortality noted in multiple prior reports. Recent studies have expanded our understanding of this entity in the era of modern immunosuppressive therapy. New clinical predictors and possible protective factors have also been identified. Recent findings This review provides an update on the epidemiology, clinical correlates, predictors, therapy and outcomes of rheumatoid vasculitis over the past decade. During this time, there has been increasing use of the treatto- target management practices and incorporation of biologic response modifiers that have revolutionized rheumatoid arthritis treatment with better disease control and overall improved outcomes. The incidence of rheumatoid vasculitis has declined significantly in the past several decades, but morbidity and mortality continue to remain high, despite aggressive treatment with cyclophosphamide or biologic agents. Hydroxychloroquine and low-dose aspirin may have a protective role. There is ongoing debate about the role of newer biological therapies in prevention, treatment or even as a trigger for rheumatoid vasculitis. Summary Rheumatoid vasculitis remains a rare yet challenging extra-articular manifestation of rheumatoid arthritis with high morbidity and mortality, despite aggressive use of disease-modifying therapy.

Original languageEnglish (US)
Pages (from-to)63-70
Number of pages8
JournalCurrent Opinion in Rheumatology
Volume27
Issue number1
DOIs
StatePublished - Jan 11 2015

Fingerprint

Rheumatoid Vasculitis
Rheumatoid Arthritis
Morbidity
Mortality
Therapeutics
Joints
Hydroxychloroquine
Biological Therapy
Practice Management
Biological Factors
Immunosuppressive Agents
Cyclophosphamide
Aspirin
Epidemiology
Incidence

Keywords

  • Biologics
  • Extra-articular manifestations
  • Rheumatoid arthritis
  • Rheumatoid vasculitis
  • Vasculitis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Rheumatoid vasculitis : An update. / Makol, Ashima; Matteson, Eric Lawrence; Warrington, Kenneth J.

In: Current Opinion in Rheumatology, Vol. 27, No. 1, 11.01.2015, p. 63-70.

Research output: Contribution to journalArticle

@article{6634d351047048b3a1aeb1bfee26f0fd,
title = "Rheumatoid vasculitis: An update",
abstract = "Purpose of review Rheumatoid vasculitis is the most serious extra-articular complication of rheumatoid arthritis, with high morbidity and mortality noted in multiple prior reports. Recent studies have expanded our understanding of this entity in the era of modern immunosuppressive therapy. New clinical predictors and possible protective factors have also been identified. Recent findings This review provides an update on the epidemiology, clinical correlates, predictors, therapy and outcomes of rheumatoid vasculitis over the past decade. During this time, there has been increasing use of the treatto- target management practices and incorporation of biologic response modifiers that have revolutionized rheumatoid arthritis treatment with better disease control and overall improved outcomes. The incidence of rheumatoid vasculitis has declined significantly in the past several decades, but morbidity and mortality continue to remain high, despite aggressive treatment with cyclophosphamide or biologic agents. Hydroxychloroquine and low-dose aspirin may have a protective role. There is ongoing debate about the role of newer biological therapies in prevention, treatment or even as a trigger for rheumatoid vasculitis. Summary Rheumatoid vasculitis remains a rare yet challenging extra-articular manifestation of rheumatoid arthritis with high morbidity and mortality, despite aggressive use of disease-modifying therapy.",
keywords = "Biologics, Extra-articular manifestations, Rheumatoid arthritis, Rheumatoid vasculitis, Vasculitis",
author = "Ashima Makol and Matteson, {Eric Lawrence} and Warrington, {Kenneth J}",
year = "2015",
month = "1",
day = "11",
doi = "10.1097/BOR.0000000000000126",
language = "English (US)",
volume = "27",
pages = "63--70",
journal = "Current Opinion in Rheumatology",
issn = "1040-8711",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Rheumatoid vasculitis

T2 - An update

AU - Makol, Ashima

AU - Matteson, Eric Lawrence

AU - Warrington, Kenneth J

PY - 2015/1/11

Y1 - 2015/1/11

N2 - Purpose of review Rheumatoid vasculitis is the most serious extra-articular complication of rheumatoid arthritis, with high morbidity and mortality noted in multiple prior reports. Recent studies have expanded our understanding of this entity in the era of modern immunosuppressive therapy. New clinical predictors and possible protective factors have also been identified. Recent findings This review provides an update on the epidemiology, clinical correlates, predictors, therapy and outcomes of rheumatoid vasculitis over the past decade. During this time, there has been increasing use of the treatto- target management practices and incorporation of biologic response modifiers that have revolutionized rheumatoid arthritis treatment with better disease control and overall improved outcomes. The incidence of rheumatoid vasculitis has declined significantly in the past several decades, but morbidity and mortality continue to remain high, despite aggressive treatment with cyclophosphamide or biologic agents. Hydroxychloroquine and low-dose aspirin may have a protective role. There is ongoing debate about the role of newer biological therapies in prevention, treatment or even as a trigger for rheumatoid vasculitis. Summary Rheumatoid vasculitis remains a rare yet challenging extra-articular manifestation of rheumatoid arthritis with high morbidity and mortality, despite aggressive use of disease-modifying therapy.

AB - Purpose of review Rheumatoid vasculitis is the most serious extra-articular complication of rheumatoid arthritis, with high morbidity and mortality noted in multiple prior reports. Recent studies have expanded our understanding of this entity in the era of modern immunosuppressive therapy. New clinical predictors and possible protective factors have also been identified. Recent findings This review provides an update on the epidemiology, clinical correlates, predictors, therapy and outcomes of rheumatoid vasculitis over the past decade. During this time, there has been increasing use of the treatto- target management practices and incorporation of biologic response modifiers that have revolutionized rheumatoid arthritis treatment with better disease control and overall improved outcomes. The incidence of rheumatoid vasculitis has declined significantly in the past several decades, but morbidity and mortality continue to remain high, despite aggressive treatment with cyclophosphamide or biologic agents. Hydroxychloroquine and low-dose aspirin may have a protective role. There is ongoing debate about the role of newer biological therapies in prevention, treatment or even as a trigger for rheumatoid vasculitis. Summary Rheumatoid vasculitis remains a rare yet challenging extra-articular manifestation of rheumatoid arthritis with high morbidity and mortality, despite aggressive use of disease-modifying therapy.

KW - Biologics

KW - Extra-articular manifestations

KW - Rheumatoid arthritis

KW - Rheumatoid vasculitis

KW - Vasculitis

UR - http://www.scopus.com/inward/record.url?scp=84918497082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918497082&partnerID=8YFLogxK

U2 - 10.1097/BOR.0000000000000126

DO - 10.1097/BOR.0000000000000126

M3 - Article

C2 - 25405822

AN - SCOPUS:84918497082

VL - 27

SP - 63

EP - 70

JO - Current Opinion in Rheumatology

JF - Current Opinion in Rheumatology

SN - 1040-8711

IS - 1

ER -